Home
Bergithe Eikeland Oftedal's picture

Bergithe Eikeland Oftedal

Researcher
  • E-mailbergithe.oftedal@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

I am a molecular biologist working in the field of immunogenetics focusing on endocrine autoimmune disease. Since my dissertation in 2012 at the University of Bergen I continued as a post-Doc with a one-year stay with Professor Hamish Scott at the University of Adelaide working with genetics. I was further awarded a mobility grant from the Norwegian Research council spending two years with Professor Georg Holländer at the University of Oxford working with T cell development in the thymus. Since 2019 I have been employed as a senior researcher in the KG Jebsen Centre for Autoimmune Diseases, and I was recently awarded the prestigious Excellence Emerging Investigator grant from the Novo Nordic foundation, starting January 2022. My long-term goal is to characterise genetic and molecular mechanisms of gene regulation within the adaptive immune system that are crucial for the development of tolerant T cells and B cells and combine this knowledge in multivariant disease models to better predict the onset of autoimmune tissue destruction. In addition, I am ambitious to extend my international network with the possibility for long-term collaborations.

Upcomming 2022: 

Invited speaker at European Congress of Endocrinology (ECE) 2022, 21–24 May 2022 in Milan Italy, and at the 20th Biennial Meeting of the European Society for Immunodeficiencies (ESID), Gothenburg, Sweden, 12-15 October, 2022.

2016:    

Invited speaker, 12th Annual Symposium on Primary Immunodeficiency Diseases, California, USA

Selected speaker at the 43rd Scandinavian Society for Immunology meeting, Turku, Finland.

       

2015

Selected speaker at The Thymus Meeting 2015, Venice, Italy

Invited speaker at the Norwegian Immunological Society annual meeting

Academic article
  • Show author(s) (2022). Extrathymic expression of Aire controls the induction of effective T<inf>H</inf>17 cell-mediated immune response to Candida albicans. Nature Immunology. 1098-1108.
  • Show author(s) (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
  • Show author(s) (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
  • Show author(s) (2021). The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function. Communications Biology.
  • Show author(s) (2021). Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine (JEM).
  • Show author(s) (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
  • Show author(s) (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
  • Show author(s) (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
  • Show author(s) (2018). Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
  • Show author(s) (2018). 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clinical and Experimental Immunology. 1-5.
  • Show author(s) (2017). T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ. Journal of Autoimmunity. 24-33.
  • Show author(s) (2017). Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I. Autoimmunity. 211-222.
  • Show author(s) (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
  • Show author(s) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
  • Show author(s) (2016). A variant in the BACH2 gene is associated with susceptibility to autoimmune addison's disease in humans. Journal of Clinical Endocrinology and Metabolism (JCEM). 3865-3869.
  • Show author(s) (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
  • Show author(s) (2015). Revealing missing human protein isoforms based on Ab initio prediction, RNA-seq and proteomics. Scientific Reports.
  • Show author(s) (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
  • Show author(s) (2015). 8q13.1-q13.2 deletion associated with inferior cerebellar vermian hypoplasia and digital anomalies: A new syndrome? Pediatric Neurology. 230-234.e1.
  • Show author(s) (2014). Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
  • Show author(s) (2014). ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism (JCEM). E1784-E1792.
  • Show author(s) (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
  • Show author(s) (2013). Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
  • Show author(s) (2012). Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
  • Show author(s) (2011). Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
  • Show author(s) (2010). Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
  • Show author(s) (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
  • Show author(s) (2008). AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
  • Show author(s) (2005). Ligand-dependent protein interactions of the estrogen receptors using the yeast two-hybrid system. Annals of the New York Academy of Sciences. 420-425.
Masters thesis
  • Show author(s) (2005). Exploring protein-protein interactions between ligand activated transcription factors using the yeast two-hybrid system.
Doctoral dissertation
  • Show author(s) (2019). Exploring and redefining Autoimmune polyendocrine syndrome type 1.
  • Show author(s) (2012). Autoimmune polyendocrine syndrome type I –novel diagnostic assays and immune regulation.
Academic chapter/article/Conference paper
  • Show author(s) (2019). The Natural History of APS1. 7 pages.
  • Show author(s) (2019). Aire Mutations and Autoimmune Diseases. 24 pages.
Abstract
  • Show author(s) (2013). Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
  • Show author(s) (2012). Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
  • Show author(s) (2010). Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
Poster
  • Show author(s) (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.
Academic literature review
  • Show author(s) (2021). B cells and autoantibodies in aire deficiency. Biomedicines. 1-15.
  • Show author(s) (2020). The prospects of single-cell analysis in autoimmunity. Scandinavian Journal of Immunology. 1-15.
  • Show author(s) (2020). New ERA of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology. 1-23.
  • Show author(s) (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology. 8-15.

More information in national current research information system (CRIStin)

Utvalgte publikasjoner:

2021:

Transcriptional Changes in Regulatory T Cells From Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing.

Berger AH, Bratland E, Sjøgren T, Heimli M, Tyssedal T, Bruserud Ø, Johansson S, Husebye ES, Oftedal BE, Wolff ASB.

Front Immunol. 2021 Aug 30;12:722860. doi: 10.3389/fimmu.2021.722860. eCollection 2021.

 

Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation

Yael Goldfarb, Tal Givony, Noam Kadouri, Jan Dobeš, Cristina Peligero-Cruz, Itay Zalayat, Golda Damari, Bareket Dassa, Shifra Ben-Dor, Yael Gruper, Bergithe E Oftedal, Eirik Bratland, Martina M Erichsen, Amund Berger, Ayelet Avin, Shir Nevo, Uku Haljasorg, Yael Kuperman, Adi Ulman, Rebecca Haffner-Krausz, Ziv Porat, Ulus Atasoy, Dena Leshkowitz, Eystein S Husebye, Jakub Abramson

J Exp Med. 2021 Nov 1;218(11):e20201076. doi: 10.1084/jem.20201076. Epub 2021 Sep 3.

 

The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function

Bergithe E Oftedal, Stefano Maio, Adam Handel, Madeleine PJ White, Duncan Howie, Simon Davis, Nicolas Prevot, Ioanna A. Rota, Mary E Deadman, Benedikt M Kessler, Roman Fischer, Nikolaus S Trede, Erdinc Sezgin, Rick M Maizels, Georg A Holländer

Nature Communications Biology, Commun Biol 4, 681 (2021). https://doi.org/10.1038/s42003-021-02203-0

 

The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease

Anette Boe Wolff, Lars Breivik, Karl Ove Hufthammer, Marianne Aardal Grytaas, Eirik Bratland, Eystein Sverre Husebye, and Bergithe Eikeland Oftedal

DOI: https://doi.org/10.1530/EJE-20-1268, Volume/Issue: Volume 184: Issue 4, Page Range: 607–615

 

2020:

GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.

D Eriksson, EC Røyrvik, M Aranda-Guillén, AH Berger, N Landegren, HA Alvarez, Å Hallgren, M Grytaas, S Ström, E Bratland, I Botusan, BE Oftedal ,…, S Johansson, O Kämpe, ES Husebye.

Nat Commun. 2021 Feb 11;12(1):959. doi: 10.1038/s41467-021-21015-8.

 

2019:

Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.

Aslaksen S, Methlie P, Vigeland MD, Jøssang DE, Wolff AB, Sheng Y, Oftedal BE, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

Front Endocrinol (Lausanne). 2019 Sep 27;10:648. doi: 10.3389/fendo.2019.00648.

 

Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.

Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

J Transl Autoimmun. 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.

 

2018

21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I.

Berglund A, Cleemann L, Oftedal BE, Holm K, Husebye ES, Gravholt CH.

Clin Exp Immunol. 2018 Oct 29. doi: 10.1111/cei.13231. PMID: 30372540

 

Oral microbiota in autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.

J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. PMID: 29503707

 

2017

Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune

Polyendocrine Syndrome Type 1.

Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.

Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.

PMID: 28919897

 

Salivary gland dysfunction in patients with autoimmune polyendocrine syndrome type I

Bergithe E. Oftedal, Mihaela Cuida, Martina M. Erichsen, Maria Tveiterås, Anja Østre, Daniel Hammenfors, Malin Johnsson, Kai Kisand, Reinhild Klein, Roland Jonsson, Anette S. B. Wolff..

Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7. PMID: 28686485

 

Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1. Elizaveta M. Orlova, Leila S. Sozaeva, Maria A. Kareva, Bergithe E. Oftedal, Anette S.B. Wolff, Lars Breivik, Ekaterina Y. Zakharova, Olle Kämpe, Per M. Knappskog, Valentina A. Peterkova, Eystein S. Husebye. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3546-3556. doi: 10.1210/jc.2017-00139. PMID: 28911151

 

T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ

Oftedal, B.E., Lundgren, B.A., Hamm, D., Finstermeier, K., Gan, P.Y., Holdsworth, S.R., Hahn, C.N., Schreiber, A.W., and Scott, H.S.

J Autoimmun. 2017 Mar 15. pii: S0896-8411(16)30344-4. doi: 10.1016/j.jaut.2017.03.002. [Epub ahead of print]. PMID: 28318808

 

2016:

A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans

Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, Pearce SH, Mitchell AL.

J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869. Epub 2016 Sep 28. PMID: 27680876

 

A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jørgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES.

J Clin Endocrinol Metab. 2016 Jun 2:jc20161821. [Epub ahead of print] PMID: 27253668

 

2015:

Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases

Bergithe E. Oftedal, Alexander Hellesen, Martina Moter Erichsen, Eirik Bratland, Ayelet Vardi, Jaakko Perheentupa, E. Helen Kemp, Torunn Fiskerstrand, Marte K. Viken, Anthony P. Weetman, Sarel J. Fleishman, Siddharth Banka, William G. Newman, W.A.C Sewell, Leila S. Sozaeva, Tetyana Zayats, Kristoffer Haugarvoll, Elizaveta M. Orlova, Jan Haavik, Stefan Johansson, Per M. Knappskog, Kristian Løvås, Anette S. B. Wolff, Jakub Abramson, Eystein S. Husebye

Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028

Citations: 54 (webofknowledge.com)

Impact factor: 24.1

2022-2027           “21-Hydroxylase reactive B cells and their immunotherapeutic potential in autoimmune Addison’s disease”. Funded by the Novo Nordic Fundation. 10 000 000 DKK. Oftedal is the project leader.

2021-2024           “Will B-cell tell the tales? Autoimmune B cells in autoimmune Addison’s disease”. Funded by the Regional Health Authorities. 3 000 000 NOK, Oftedal is the project leader.

2017-2021          “KG Jebsen center for autoimmune disorders”. A national centre established in Bergen, where Oftedal is a principal investigator. Funded by KG Jebsen, 18 000 000.

2017-2020          “Identification of novel monogenic autoimmune syndromes”. Partners are Husebye, Bratland and Wolff. Funded by Norwegian Research Council, 4 000 000 NOK.

2016-2019          “New perspectives on regulation of peripheral tissue antigen expression within the thymus”. Oftedal is the project leader. Partners are Georg Holländer and Eystein Husebye. Funded by the Norwegian Research Council. 3 328 000 NOK